New hope for rare lung infection: epetraborole trial begins

NCT ID NCT07301320

Recruiting now Disease control Sponsor: Kevin Winthrop Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus. About 84 adults will take either a low or high dose of the drug or a placebo for 84 days. Researchers will check if symptoms improve and if the infection clears from sputum samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epetraborole
What this could lead to: If it works, this could point toward a new treatment for a hard-to-treat lung infection that currently has limited options.
What could go wrong: This is an early Phase 2 trial with only 84 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS COMPLEX LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycobacterial infectious disease Mycobacterium Infections, Nontuberculous pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM ABSCESSUS INFECTION

Contacts and locations

Locations

Oregon Health & Science University
RECRUITING

Portland, Oregon, 97239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.